The Use of Triamcinolone Injection in Treatment of Refractory Benign Esophageal Stricture in Children

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy of Intra-lesional triamcinolone injection in the management of refractory benign esophageal Stricture in children.

Detailed Description
-----------------
Oesophageal stricture is a commonly encountered clinical problem, especially in gastroenterology. It occurs due to narrowing of oesophagus, which results in swallowing difficulty. Oesophageal stricture has two major types: benign and malignant. Malignant type results from carcinoma but benign type has different causes. Amongst benign aetiologies, gastrointestinal reflux disease (GERD), peptic injury, oesophageal webs, radiation damage, caustic swallowing and anastomotic strictures are most common. Corrosive intake is an important public health issue in developed countries and its incidence is still increasing in developing countries. The problem is largely unreported and its exact prevalence cannot be figured out due to the insufficient reporting or personal experience. Corrosives materials can damage the bodies' tissues, as they come in contact with them. They are usually utilised to clean metals. It can cause severe health hazard, if swallowed accidentally or intentionally. Epidemiological studies have documented corrosive intake as the third most common cause of poisoning in adults. The most common symptom of oesophageal stricture is progressive dysphagia to solids followed by inability to tolerate liquids. These strictures are diagnosed most commonly by using barium swallow, endoscopy and biopsy. Endoscopic dilatation is the most applicable method to treat oesophageal strictures, and proton pump inhibitors (PPIs) are also used to inhibit acid production. According to the Kochman criteria, refractory or recurrent strictures are defined as an anatomic restriction because of a cicatricial luminal compromise or fibrosis resulting in clinical symptoms of dysphagia in the absence of endoscopic evidence of inflammation. This may occur as the result of either an inability to successfully remediate the anatomic problem to a diameter of at least 14 mm over five sessions at two-week intervals (refractory); or as a result of an inability to maintain a satisfactory luminal diameter for four weeks once the target diameter of 14 mm has been achieved (recurrent). This definition is not meant to include patients with an inflammatory stricture (which will not resolve until the inflammation subsides), or those with a satisfactory diameter but having dysphagia on the basis of neuromuscular dysfunction (for example those with dysphagia due to postoperative and/or postradiation therapy). Esophageal rehabilitation has been carried out for many years with different techniques, depending on the experience of each physician, esophageal prostheses or splints, dilations with balloons or Savary-Gilliard plugs, Hurst dilators, etc., have been used, but in reality, there is no worldwide standardization for the management of these patients and even less so for the use of certain substances such as triamcinolone acetonide applied intralesionally, or more recently, topical mitomycin C. Triamcinolone acetonide is a synthetic corticosteroid with a preventive effect on collagen synthesis, fibrosis, and chronic cicatrization that has been used for many years, applied in intralesional injection after esophageal dilations for the purpose of delaying cicatrization and thus reducing the number of dilations. Presently, through many studies, it has been concluded that intralesional corticosteroid injections can be added to standard treatment for corrosive oesophageal stricture. International literature exhibited that intralesional steroid injections help in increasing the diameter because of its anti-inflammatory action.

Official Title
-----------------
The Use of Triamcinolone Injection in Treatment of Refractory Benign Esophageal Stricture in Children

Conditions
-----------------
Esophageal Stricture

Intervention / Treatment
-----------------
* Drug: Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients admitted to Assiut University Children Hospital with: refractory benign esophageal stricture(inability to successfully remediate the anatomic problem to a diameter of at least 14 mm over five sessions at two-week interval) inability to maintain a satisfactory luminal diameter for four weeks once the target diameter of 14 mm has been achieved Exclusion Criteria: Pharyngeal stenosis precluding endoscopic examination and dilatation tracheo-esophageal fistula, gastric cicatrization that precluded safe placement of aguidewire any patient who was unfit for general anesthesia.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: The use of Triamcinolone Injection<br>Triamcinolone acetate (40 mg/mL) | Drug: Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children<br>* Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation<br>* Other names: Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patients show improvement in dysphagia scale after five session of triamcinolone injection | number of patients show improvement in dysphagia scale after five session of triamcinolone injection | 2years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the number of patients who will show complete relieve of dysphagia after five sessions of triamcinolone injection | complete abscence of dysphagia after triamcinolone injection | 2years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
triamcinolole, refractory esophageal stricture, children